GNLKQ (GNLKQ) Stock Price & Analysis
GNLKQ (GNLKQ) rose 0.00% to USD 0 as of June 10, 2026 at 12:26 UTC, according to Nexqual real-time market data.
GNLKQ last closed at USD 0; the session ranged USD 0–0 on volume of 500 shares. Market capitalization is $10,600, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 12:26 UTC.
Key Statistics (as of June 10, 2026 at 12:26 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 500 shares |
| Market Cap | $10,600 |
| Exchange | PNK |
Technical Analysis (GNLKQ)
Nexqual's technical model rates GNLKQ "SELL" based on 0 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 12:26 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0) |
Analyst Ratings (GNLKQ)
Wall Street analysts rate GNLKQ "None", per Nexqual as of June 10, 2026 at 12:26 UTC.
| Consensus Rating | None |
|---|
Earnings (GNLKQ)
Source: Nexqual, June 10, 2026 at 12:26 UTC.
Financials & Fundamentals (GNLKQ)
| Total Revenue | $1.58M |
|---|---|
| Revenue Growth (YoY) | -30.70% |
| Gross Margin | +19.40% |
| Operating Margin | -204.69% |
| Profit Margin | -141.05% |
| Current Ratio | 0.34 |
| Total Cash | $127,559 |
| Total Debt | $1.19M |
| Free Cash Flow | $-1.75M |
Source: Nexqual, June 10, 2026 at 12:26 UTC.
Financial Health Score (GNLKQ)
Nexqual rates GNLKQ's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 12:26 UTC.
| Growth | Critical — Revenue -31% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $128K cash vs $1M debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Mixed — No data |
Ownership (GNLKQ)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 265.02M |
Source: Nexqual, June 10, 2026 at 12:26 UTC.
Leadership (GNLKQ)
GNLKQ is led by Bernard L. Kasten Jr. (age 79), Executive Chairman, Chief Executive Officer, President and Member of Scientific Advisory Board, per Nexqual as of June 10, 2026 at 12:26 UTC.
| Executive Chairman, Chief Executive Officer, President and Member of Scientific Advisory Board | Bernard L. Kasten Jr. (age 79) |
|---|---|
| Founder, Chief Science Officer, Treasurer, Secretary, Director & Member of Scientific Advisory Board | Robert P. Ricciardi (age 78) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TNGNQ | TENGION INC | USD 0 | ▲ 0% |
| PFND | PATHFINDER CELL THERAPY INC | USD 0 | ▲ 0% |
| PZRXQ | PHASERX INC | USD 0 | ▲ 0% |
| BSSP | BASSLINE PRODUCTIONS INC | USD 0 | ▲ 0% |
| IGNE | IGENE BIOTECHNOLOGY INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:26 UTC. This page is informational and not investment advice.